Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Conbriza
CONBRIZA 20 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 4
HOS-209621 · Präparat HOS-154337
There were no significant pharmacokinetic interactions between bazedoxifene and the following
medicinal products: ibuprofen, atorvastatin, azithromycin, or an antacid containing aluminium and
magnesium hydroxide. Based on in vitro bazedoxifene plasma protein binding characteristics, drug
interactions with warfarin, digoxin and diazepam are unlikely.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ibuprofen (HOS-087884) atorvastatin (HOS-086304) digoxin (HOS-086172) magnesium hydroxide (HOS-088789) azithromycin (HOS-088112) diazepam (HOS-085904) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-20T02:00:00Z · SHA-256 1c409a8a8e5a5d9f881382d3102b23f5a4c7f5222a930c0873e9e92636b8ccc8 · Passage a4b94f0f0ce957f72a9e2d9bc141f2807d7d0636f999771f3753dd84331c97c9 · Zeichen 891–1242 im Abschnitt
Wechselwirkungen · Modigraf
Modigraf 0.2 mg granules for oral suspension Modigraf 1 mg granules for oral suspension · Abschnitt 4.5 · PDF-Seite 10–11
HOS-209742 · Präparat HOS-154375
10
Medicinal products which have effects on tacrolimus
Drug/Substance Class or Drug interaction effect Recommendations concerning co-
Name administration
Grapefruit or grapefruit juice May increase tacrolimus Avoid grapefruit or grapefruit
whole blood trough juice.
concentrations and increase
the risk of serious adverse
reactions (e.g., neurotoxicity,
QT prolongation) [see
section 4.4].
Ciclosporin May increase tacrolimus The simultaneous use of
whole blood trough ciclosporin and tacrolimus should
concentrations. In addition, be avoided [see section 4.4].
synergistic/additive
nephrotoxic effects can
occur.
Products known to have May enhance nephrotoxic or Concurrent use of tacrolimus with
nephrotoxic or neurotoxic neurotoxic effects of drugs known to have nephrotoxic
effects: tacrolimus. effects should be avoided. When
aminoglycosides, gyrase co-administration cannot be
inhibitors, vancomycin, avoided, monitor renal function
sulfamethoxazole + and other side effects and adjust
trimethoprim, NSAIDs, tacrolimus dose if needed.
ganciclovir, acyclovir,
amphotericin B, ibuprofen
cidofovir, foscarnet
Strong CYP3A4 inhibitors: May increase tacrolimus It is recommended that
antifungal agents (e.g., whole blood trough concomitant use should be
ketoconazole, itraconazole, concentrations and increase avoided. If co-administration of a
posaconazole, voriconazole), the risk of serious adverse strong CYP3A4 inhibitor is
the macrolide antibiotics reactions (e.g., unavoidable, consider omitting
(e.g., telithromycin, nephrotoxicity, the dose of tacrolimus the day the
troleandomycin, neurotoxicity, QT strong CYP3A4 inhibitor is
clarithromycin, josamycin), prolongation) which requires initiated. Reinitiate tacrolimus the
HIV protease inhibitors (e.g., close monitoring [see next day at a reduced dose based
ritonavir, nelfinavir, section 4.4]. on tacrolimus blood
saquinavir), HCV protease Rapid and sharp increases in concentrations. Changes in both
inhibitors (e.g., telaprevir, tacrolimus levels may occur, tacrolimus dose and/or dosing
boceprevir, and the as early as within 1-3 days frequency should be
combination of ombitasvir after co-administration, individualized and adjusted as
and paritaprevir with despite immediate reduction needed based on tacrolimus
ritonavir, when used with and of tacrolimus dose. Overall trough concentrations, which
without dasabuvir), tacrolimus exposure may should be assessed at initiation,
nefazodone, the increase > 5 fold. When monitored frequently throughout
pharmacokinetic enhancer ritonavir combinations are (starting within the first few days)
cobicistat and the kinase co-administered, tacrolimus and re-evaluated on and after
inhibitors idelalisib, ceritinib. exposure may increase > 50 completion of the CYP3A4
Strong interactions have also fold. inhibitor. Upon completion,
been observed with the Nearly all patients may appropriate dose and dosing
macrolide antibiotic require a reduction in frequency of tacrolimus should be
erythromycin tacrolimus dose and guided by tacrolimus blood
temporary interruption of concentrations. Monitor renal
tacrolimus may also be function, ECG for QT
necessary. prolongation, and other side
effects closely.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): foscarnet (HOS-110484) sulfamethoxazole (HOS-084533) ceritinib (HOS-086215) josamycin (HOS-113844) nefazodone (HOS-084519) nelfinavir (HOS-084520) ibuprofen (HOS-087884) protease (HOS-085623) amphotericin B (HOS-109312) trimethoprim (HOS-085184) ketoconazole (HOS-084513) cobicistat (HOS-088111) cidofovir (HOS-110482) grapefruit juice (HOS-088787) dasabuvir (HOS-110302) voriconazole (HOS-084524) telaprevir (HOS-090618) telithromycin (HOS-084523) itraconazole (HOS-084516) saquinavir (HOS-084522) ombitasvir (HOS-110300) boceprevir (HOS-090617) clarithromycin (HOS-084517) vancomycin (HOS-110486) erythromycin (HOS-084514) troleandomycin (HOS-090575) ritonavir (HOS-084521) ganciclovir (HOS-085194) paritaprevir (HOS-110301) acyclovir (HOS-088527) posaconazole (HOS-085622) idelalisib (HOS-116811)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-03T17:00:00Z · SHA-256 1a464ac051c5783e49ce08a9d103d0d319997aa4add60584450928c1b11144a7 · Passage 84292deca9b273b57aafc577a96618c8f1b67362b0e5f3bec58af5bfd6d618af · Zeichen 1995–6929 im Abschnitt
Wechselwirkungen · Stelara
STELARA 130 mg concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 6
HOS-120458 · Präparat HOS-095137
In the population pharmacokinetic analyses of the phase 3 studies, the effect of the most frequently
used concomitant medicinal products in patients with psoriasis (including paracetamol, ibuprofen,
acetylsalicylic acid, metformin, atorvastatin, levothyroxine) on pharmacokinetics of ustekinumab was
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ibuprofen (HOS-087884) atorvastatin (HOS-086304) metformin (HOS-091032) levothyroxine (HOS-086339)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-16T15:45:00Z · SHA-256 fc1cff87559a2e47313d4a4a9f51b34035748452bff7f09d92aede3e4395271b · Passage 31d55224a6bb32692956e2b9243a684e26273eaf4499202c7f4907df97c4c7e1 · Zeichen 498–797 im Abschnitt
Wechselwirkungen · Stelara
STELARA 45 mg solution for injection STELARA 45 mg solution for injection in pre-filled syringe STELARA 90 mg solution for injection in pre-filled syringe · Abschnitt 4.5 · PDF-Seite 32
HOS-120493 · Präparat HOS-095137
In the population pharmacokinetic analyses of the phase 3 studies, the effect of the most frequently
used concomitant medicinal products in patients with psoriasis (including paracetamol, ibuprofen,
acetylsalicylic acid, metformin, atorvastatin, levothyroxine) on pharmacokinetics of ustekinumab was
explored. There were no indications of an interaction with these concomitantly administered medicinal
products. The basis for this analysis was that at least 100 patients (> 5% of the studied population)
were treated concomitantly with these medicinal products for at least 90% of the study period. The
pharmacokinetics of ustekinumab was not impacted by concomitant use of MTX, NSAIDs, 6-
mercaptopurine, azathioprine and oral corticosteroids in patients with psoriatic arthritis, Crohn’s
disease or ulcerative colitis, or prior exposure to anti-TNFα agents, in patients with psoriatic arthritis
or Crohn’s disease or by prior exposure to biologics (i.e. anti-TNFα agents and/or vedolizumab) in
patients with ulcerative colitis.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ibuprofen (HOS-087884) atorvastatin (HOS-086304) mercaptopurine (HOS-085568) vedolizumab (HOS-120460) azathioprine (HOS-089001) metformin (HOS-091032) levothyroxine (HOS-086339)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-16T15:45:00Z · SHA-256 fc1cff87559a2e47313d4a4a9f51b34035748452bff7f09d92aede3e4395271b · Passage d7992329e08441a34876eaaebb05cd7e3c6d36484de465d2bb947d8ed5148c63 · Zeichen 498–1527 im Abschnitt
Wechselwirkungen · Stelara
STELARA 45 mg solution for injection in pre-filled pen STELARA 90 mg solution for injection in pre-filled pen · Abschnitt 4.5 · PDF-Seite 63
HOS-120526 · Präparat HOS-095137
In the population pharmacokinetic analyses of the phase 3 studies, the effect of the most frequently
used concomitant medicinal products in patients with psoriasis (including paracetamol, ibuprofen,
acetylsalicylic acid, metformin, atorvastatin, levothyroxine) on pharmacokinetics of ustekinumab was
explored. There were no indications of an interaction with these concomitantly administered medicinal
products. The basis for this analysis was that at least 100 patients (> 5% of the studied population)
were treated concomitantly with these medicinal products for at least 90% of the study period. The
pharmacokinetics of ustekinumab was not impacted by concomitant use of MTX, NSAIDs, 6-
mercaptopurine, azathioprine and oral corticosteroids in patients with psoriatic arthritis, Crohn’s
disease or ulcerative colitis, or prior exposure to anti-TNFα agents, in patients with psoriatic arthritis
or Crohn’s disease or by prior exposure to biologics (i.e. anti-TNFα agents and/or vedolizumab) in
patients with ulcerative colitis.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ibuprofen (HOS-087884) atorvastatin (HOS-086304) mercaptopurine (HOS-085568) vedolizumab (HOS-120460) azathioprine (HOS-089001) metformin (HOS-091032) levothyroxine (HOS-086339)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-16T15:45:00Z · SHA-256 fc1cff87559a2e47313d4a4a9f51b34035748452bff7f09d92aede3e4395271b · Passage d7992329e08441a34876eaaebb05cd7e3c6d36484de465d2bb947d8ed5148c63 · Zeichen 498–1527 im Abschnitt
Wechselwirkungen · Raloxifene Teva
Raloxifene Teva 60 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 4
HOS-210833 · Präparat HOS-154595
The influence of concomitant medication on raloxifene plasma concentrations was evaluated in the
prevention and treatment trials. Frequently co-administered medicinal products included: paracetamol,
non-steroidal anti-inflammatory drugs (such as acetylsalicylic acid, ibuprofen, and naproxen), oral
antibiotics, H1 antagonists, H2 antagonists, and benzodiazepines. No clinically relevant effects of the
co-administration of the agents on raloxifene plasma concentrations were identified.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ibuprofen (HOS-087884) naproxen (HOS-087936)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2021-09-27T11:30:00Z · SHA-256 bbf6706a7418bb5343336909f5773d58520cc2fd4c0b1b303b9821080fd9b117 · Passage ff1bd699d24e5c90d6c515ae35e2104a39943ff3a80b5761ddb417dc3aac9781 · Zeichen 824–1311 im Abschnitt
Wechselwirkungen · Prevenar 13
Prevenar 13 suspension for injection pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) · Abschnitt 4.5 · PDF-Seite 6
HOS-121810 · Präparat HOS-095437
Data from a postmarketing clinical study evaluating the impact of prophylactic use of antipyretics
(ibuprofen and paracetamol) on the immune response to Prevenar 13 suggest that administration of
paracetamol concomitantly or within the same day of vaccination may reduce the immune response to
Prevenar 13 after the infant series. Responses to the booster dose administered at 12 months were
unaffected. The clinical significance of this observation is unknown.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ibuprofen (HOS-087884)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-05T10:20:00Z · SHA-256 6a86f7a7aa34133091bc2ef414feeace046fcc5a28168dfdcb5f7fd2514bcdce · Passage bed52be2046dc8604f1cbcfd684b9ce2b95801976872bf7d2a8bfb856a013046 · Zeichen 692–1153 im Abschnitt
Wechselwirkungen · Prevenar 13
Prevenar 13 suspension for injection in single dose vial pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) · Abschnitt 4.5 · PDF-Seite 31
HOS-121871 · Präparat HOS-095437
Data from a postmarketing clinical study evaluating the impact of prophylactic use of antipyretics
(ibuprofen and paracetamol) on the immune response to Prevenar 13 suggest that administration of
paracetamol concomitantly or within the same day of vaccination may reduce the immune response to
Prevenar 13 after the infant series. Responses to the booster dose administered at 12 months were
unaffected. The clinical significance of this observation is unknown.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ibuprofen (HOS-087884)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-05T10:20:00Z · SHA-256 6a86f7a7aa34133091bc2ef414feeace046fcc5a28168dfdcb5f7fd2514bcdce · Passage bed52be2046dc8604f1cbcfd684b9ce2b95801976872bf7d2a8bfb856a013046 · Zeichen 692–1153 im Abschnitt
Wechselwirkungen · Prevenar 13
Prevenar 13 suspension for injection in multidose container pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) · Abschnitt 4.5 · PDF-Seite 56
HOS-121933 · Präparat HOS-095437
Data from a postmarketing clinical study evaluating the impact of prophylactic use of antipyretics
(ibuprofen and paracetamol) on the immune response to Prevenar 13 suggest that administration of
paracetamol concomitantly or within the same day of vaccination may reduce the immune response to
Prevenar 13 after the infant series. Responses to the booster dose administered at 12 months were
unaffected. The clinical significance of this observation is unknown.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ibuprofen (HOS-087884)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-05T10:20:00Z · SHA-256 6a86f7a7aa34133091bc2ef414feeace046fcc5a28168dfdcb5f7fd2514bcdce · Passage bed52be2046dc8604f1cbcfd684b9ce2b95801976872bf7d2a8bfb856a013046 · Zeichen 692–1153 im Abschnitt
Wechselwirkungen · Clopidogrel/Acetylsalicylic acid Zentiva (previously DuoCover)
Clopidogrel/Acetylsalicylic acid Zentiva 75 mg/75 mg film-coated tablets Clopidogrel/Acetylsalicylic acid Zentiva 75 mg/100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-212235 · Präparat HOS-154856
Experimental data suggest that ibuprofen may inhibit the effect of low dose aspirin on platelet
aggregation when they are dosed concomitantly. However, the limitations of these data and the
uncertainties regarding extrapolation of ex vivo data to the clinical situation imply that no firm
conclusions can be made for regular ibuprofen use, and no clinically relevant effect is considered to be
likely for occasional ibuprofen use (see section 5.1).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ibuprofen (HOS-087884)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2019-11-13T14:36:00Z · SHA-256 fdf7b1939833e55bbc6a1c8732c66c147ac4404b0347a1c2e50406556ee7b8c0 · Passage a21ab56b2d276d36905bb900ef298326a19eb044a93e3de0e6cd9e5519ec5354 · Zeichen 2328–2776 im Abschnitt
Wechselwirkungen · Entacapone Teva
Entacapone Teva 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 4–5
HOS-213543 · Präparat HOS-155128
4
Entacapone binds to human albumin binding site II which also binds several other medicinal products,
including diazepam and ibuprofen. Clinical interaction studies with diazepam and non-steroidal anti-
inflammatory medicinal products have not been carried out. According to in vitro studies, significant
displacement is not anticipated at therapeutic concentrations of the medicinal products.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ibuprofen (HOS-087884) diazepam (HOS-085904)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2021-09-28T17:49:00Z · SHA-256 a1bd223632cc773f7d6b9c4c6c3717b6bb040156eb55488dc0e81428b647ce20 · Passage 41f50414f9ca397c55ddda9cacd770b556ff129a5bf3bc91a9c65853f8ab6a94 · Zeichen 1382–1777 im Abschnitt
Wechselwirkungen · NexoBrid
NexoBrid 5 g powder and gel for gel · Abschnitt 4.5 · PDF-Seite 7
HOS-213871 · Präparat HOS-155226
The medicinal product, when absorbed, is an inhibitor of cytochrome P450 2C8 (CYP2C8) and P450 2C9
(CYP2C9). This should be taken into account if this medicinal product is used in patients receiving
CYP2C8 substrates (including amiodarone, amodiaquine, chloroquine, fluvastatin, paclitaxel, pioglitazone,
repaglinide, , and torasemide) and CYP2C9 substrates (including ibuprofen, tolbutamide, glipizide,
losartan, celecoxib, warfarin, and phenytoin).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): glipizide (HOS-109460) losartan (HOS-087482) ibuprofen (HOS-087884) celecoxib (HOS-113199) amodiaquine (HOS-146807) fluvastatin (HOS-086305) pioglitazone (HOS-089663) paclitaxel (HOS-087959) amiodarone (HOS-085596) phenytoin (HOS-084531) warfarin (HOS-085950) repaglinide (HOS-086935) tolbutamide (HOS-086568) chloroquine (HOS-109138)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-03T16:44:00Z · SHA-256 0e966e92cc19adf0ef382cd0ae4ca84db51705148a696b737819286b20db4bab · Passage 93865059fa8cabd6eff57948947ccf5e585dc227295712122812666b6c809ed5 · Zeichen 558–1008 im Abschnitt
Wechselwirkungen · Duavive
DUAVIVE 0.45 mg/20 mg modified-release tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-125229 · Präparat HOS-096029
There were no significant pharmacokinetic interactions between bazedoxifene and the following
medicinal products: ibuprofen, atorvastatin and azithromycin or an antacid containing aluminium and
magnesium hydroxide.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ibuprofen (HOS-087884) atorvastatin (HOS-086304) magnesium hydroxide (HOS-088789) azithromycin (HOS-088112)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-06T02:00:00Z · SHA-256 cebc18aeeaa7e87d26ff41a36f1789bee3f7e1eaa839d2f6fdebebc62c1ef614 · Passage a577a62499078dd9cb55006a76458c5cc1225e598ac3aa7dc24c4db50e6eb2a5 · Zeichen 2546–2760 im Abschnitt
Wechselwirkungen · Entacapone Orion
Entacapone Orion 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 5
HOS-215653 · Präparat HOS-155488
Entacapone binds to human albumin binding site II which also binds several other medicinal
products, including diazepam and ibuprofen. Clinical interaction studies with diazepam and non-
steroidal anti-inflammatory medicinal products have not been carried out. According to in vitro
studies, significant displacement is not anticipated at therapeutic concentrations of the medicinal
products.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ibuprofen (HOS-087884) diazepam (HOS-085904)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-09-24T11:10:00Z · SHA-256 3eb4e83d0bea670f09b10f71bef77c228824c1e10efb8c36a0cf3aa5315b81fe · Passage 4abd1a0e077592cfbe49db5c396f8d898ff80aaffc765ec433820384ead0c629 · Zeichen 1385–1777 im Abschnitt
Wechselwirkungen · Levodopa/Carbidopa/Entacapone Orion
Levodopa/Carbidopa/Entacapone Orion 50 mg/12.5 mg/200 mg film-coated tablets Levodopa/Carbidopa/Entacapone Orion 75 mg/18.75 mg/200 mg film-coated tablets Levodopa/Carbidopa/Entacapone Orion 100 mg/25 mg/200 mg film-coated tablets Levodopa/Carbidopa/Entacapone Orion 125 mg/31.25 mg/200 mg film-coated tablets Levodopa/Carbidopa/Entacapone Orion 150 mg/37.5 mg/200 mg film-coated tablets Levodopa/Carbidopa/Entacapone Orion 175 mg/43.75 mg/200 mg film-coated tablets Levodopa/Carbidopa/Entacapone Orion 200 mg/50 mg/200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-125978 · Präparat HOS-096201
In vitro data: Entacapone binds to human albumin binding site II which also binds several other
medicinal products, including diazepam and ibuprofen. According to in vitro studies, significant
displacement is not anticipated at therapeutic concentrations of the medicinal products. Accordingly,
to date there has been no indication of such interactions.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ibuprofen (HOS-087884) diazepam (HOS-085904)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-01-22T13:17:00Z · SHA-256 0b58e7c710f75a6903225e3110b4255e26a78fbf567494b5c767ec9955060634 · Passage ad701313ca2b2e5110b8f4d56b576d2c6a09016260c2d2b0193fc03865adbe00 · Zeichen 3440–3793 im Abschnitt
Wechselwirkungen · Voriconazole Hikma (previously Voriconazole Hospira)
Voriconazole Hikma 200 mg powder for solution for infusion · Abschnitt 4.5 · PDF-Seite 17–18
HOS-130968 · Präparat HOS-096981
17
Finerenone Although not studied, voriconazole Contraindicated (see section
[CYP3A4 substrate] is likely to significantly increase 4.3)
the plasma concentrations of
finerenone.
Eplerenone Although not studied, voriconazole Contraindicated (see section
[CYP3A4 substrate] is likely to significantly increase 4.3)
the plasma concentrations of
eplerenone.
Non-steroidal anti-inflammatory drugs (NSAIDs)
[CYP2C9 substrates] Frequent monitoring for adverse
S-Ibuprofen Cmax ↑ 20% reactions and toxicity related to
Ibuprofen (400 mg single dose) S-Ibuprofen AUC0-∞ ↑ 100% NSAIDs is recommended. Dose
reduction of NSAIDs may be
Diclofenac (50 mg single dose) Diclofenac Cmax ↑ 114% needed.
Diclofenac AUC0-∞ ↑ 78%
Opioids
Long-Acting Opiates In an independent published study, Dose reduction in oxycodone and
[CYP3A4 substrates] Oxycodone Cmax ↑ 1.7-fold other long-acting opiates
Oxycodone AUC0-∞ ↑ 3.6-fold metabolised by CYP3A4
Oxycodone (10 mg single (e.g., hydrocodone) should be
dose) considered. Frequent monitoring
for opiate-associated adverse
reactions may be necessary.
Methadone (32-100 mg QD) R-methadone (active) Cmax ↑ 31% Frequent monitoring for adverse
[CYP3A4 substrate] R-methadone (active) AUCτ ↑ 47% reactions and toxicity related to
S-methadone Cmax ↑ 65% methadone, including QTc
S-methadone AUCτ ↑ 103% prolongation, is recommended.
Dose reduction of methadone
may be needed.
Short-acting Opiates Dose reduction of alfentanil,
[CYP3A4 substrates] fentanyl and other short-acting
opiates similar in structure to
Alfentanil (20 μg/kg single In an independent published study, alfentanil and metabolised by
dose, with concomitant Alfentanil AUC0-∞ ↑ 6-fold CYP3A4 (e.g., sufentanil) should
naloxone) be considered. Extended and
frequent monitoring for
Fentanyl (5 µg/kg single dose) In an independent published study, respiratory depression and other
Fentanyl AUC0-∞ ↑ 1.34-fold opiate-associated adverse
reactions is recommended.
Opioid receptor antagonists
Naloxegol Although not studied, voriconazole Contraindicated (see section
[CYP3A4 substrate] is likely to significantly increase 4.3)
the plasma concentrations of
naloxegol.
Oral contraceptives
Oral Contraceptives* Ethinylestradiol Cmax ↑ 36% Monitoring for adverse reactions
[CYP3A4 substrate; CYP2C19 Ethinylestradiol AUCτ ↑ 61% related to oral contraceptives, in
inhibitor] Norethisterone Cmax ↑ 15% addition to those for
Norethisterone/ethinylestradiol Norethisterone AUCτ ↑ 53% voriconazole, is recommended.
(1 mg/0.035 mg QD) Voriconazole Cmax ↑ 14%
Voriconazole AUCτ ↑ 46%
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfentanil (HOS-109375) diclofenac (HOS-085903) ibuprofen (HOS-087884) methadone (HOS-086198) eplerenone (HOS-089050) oxycodone (HOS-109487) finerenone (HOS-109430) naloxegol (HOS-109428) hydrocodone (HOS-109488) naloxone (HOS-109490) fentanyl (HOS-086196) sufentanil (HOS-109489)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-23T14:40:00Z · SHA-256 8f5a567ef9a1f0f0bee27abd2100fc7726dcc5281b72b1f33957fd6bcec22b38 · Passage c15a75c62801770f9555f6206fed29c8569fb1a5f9063364f5ddb780efc68271 · Zeichen 27899–32111 im Abschnitt
Wechselwirkungen · Olumiant
Olumiant 1 mg film-coated tablets Olumiant 2 mg film-coated tablets Olumiant 4 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10
HOS-134789 · Präparat HOS-097616
Transporters
In vitro, baricitinib is a substrate for organic anionic transporter (OAT)3, P-glycoprotein (Pgp), breast
cancer resistance protein (BCRP) and multidrug and toxic extrusion protein (MATE)2-K. In a clinical
pharmacology study, dosing of probenecid (an OAT3 inhibitor with strong inhibition potential)
resulted in approximately a 2-fold increase in AUC(0-∞) with no change in tmax or Cmax of baricitinib.
Consequently, in patients taking OAT3 inhibitors with a strong inhibition potential, such as
probenecid, the recommended dose of baricitinib should be reduced by half (see section 4.2). No
clinical pharmacology study has been conducted with OAT3 inhibitors with less inhibition potential.
The prodrug leflunomide rapidly converts to teriflunomide which is a weak OAT3 inhibitor and
therefore may lead to an increase in baricitinib exposure. Since dedicated interaction studies have not
been conducted, caution should be used when leflunomide or teriflunomide are given concomitantly
with baricitinib. Concomitant use of the OAT3 inhibitors ibuprofen and diclofenac may lead to
increased exposure of baricitinib, however their inhibition potential of OAT3 is less compared to
probenecid and thus a clinically relevant interaction is not expected. Coadministration of baricitinib
with ciclosporin (Pgp/BCRP inhibitor) or methotrexate (substrate of several transporters including
OATP1B1, OAT1, OAT3, BCRP, MRP2, MRP3, and MRP4) resulted in no clinically meaningful
effects on baricitinib exposure.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diclofenac (HOS-085903) ibuprofen (HOS-087884) leflunomide (HOS-089630) teriflunomide (HOS-089632) lead (HOS-085592) probenecid (HOS-085208) methotrexate (HOS-087522)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-13T16:57:00Z · SHA-256 21fbeaddabb6b542aa078c68b96c452bd5c5e255d57f8087fb5e2094fcf4ef31 · Passage a26fa7f8815a8dcc93b765e94ceb12eaba9b5b152e4a7ad339a2c22b8e854455 · Zeichen 703–2214 im Abschnitt
Wechselwirkungen · Olumiant
Olumiant 2 mg/mL oral suspension · Abschnitt 4.5 · PDF-Seite 46–47
HOS-134832 · Präparat HOS-097616
Transporters
In vitro, baricitinib is a substrate for organic anionic transporter (OAT)3, P-glycoprotein (Pgp), breast
cancer resistance protein (BCRP) and multidrug and toxic extrusion protein (MATE)2-K. In a clinical
pharmacology study, dosing of probenecid (an OAT3 inhibitor with strong inhibition potential)
resulted in approximately a 2-fold increase in AUC(0-∞) with no change in tmax or Cmax of baricitinib.
Consequently, in patients taking OAT3 inhibitors with a strong inhibition potential, such as
probenecid, the recommended dose of baricitinib should be reduced by half (see section 4.2). No
clinical pharmacology study has been conducted with OAT3 inhibitors with less inhibition potential.
The prodrug leflunomide rapidly converts to teriflunomide which is a weak OAT3 inhibitor and
therefore may lead to an increase in baricitinib exposure. Since dedicated interaction studies have not
been conducted, caution should be used when leflunomide or teriflunomide are given concomitantly
with baricitinib. Concomitant use of the OAT3 inhibitors ibuprofen and diclofenac may lead to
46
increased exposure of baricitinib, however their inhibition potential of OAT3 is less compared to
probenecid and thus a clinically relevant interaction is not expected. Coadministration of baricitinib
with ciclosporin (Pgp/BCRP inhibitor) or methotrexate (substrate of several transporters including
OATP1B1, OAT1, OAT3, BCRP, MRP2, MRP3, and MRP4) resulted in no clinically meaningful
effects on baricitinib exposure.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diclofenac (HOS-085903) ibuprofen (HOS-087884) leflunomide (HOS-089630) teriflunomide (HOS-089632) lead (HOS-085592) probenecid (HOS-085208) methotrexate (HOS-087522)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-13T16:57:00Z · SHA-256 21fbeaddabb6b542aa078c68b96c452bd5c5e255d57f8087fb5e2094fcf4ef31 · Passage 20d9845e63645fa2b1695c5c2b0a33f8e99aeb95d51d77928cf3e68fb9e52e4b · Zeichen 703–2269 im Abschnitt
Wechselwirkungen · Slenyto
Slenyto 1 mg prolonged-release tablets Slenyto 5 mg prolonged-release tablets · Abschnitt 4.5 · PDF-Seite 5
HOS-138616 · Präparat HOS-098224
Prostaglandin synthesis inhibitors (NSAIDs) such as acetylsalicylic acid and ibuprofen, given in the
evening may suppress endogenous melatonin levels in the early part of the night by up to 75%. If
possible, administration of NSAIDs should be avoided in the evening.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ibuprofen (HOS-087884)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-10T15:35:00Z · SHA-256 17494391b1b166184a1056469270f628e4597dda5631ec4cd470a78d59405d08 · Passage 57e30cc2e1755a5fafeebae3b48e94c855e8562b3a320315229423fbf181adad · Zeichen 3247–3513 im Abschnitt
Wechselwirkungen · Tacforius
Tacforius 0.5 mg prolonged-release hard capsules Tacforius 1 mg prolonged-release hard capsules Tacforius 3 mg prolonged-release hard capsules Tacforius 5 mg prolonged-release hard capsules · Abschnitt 4.5 · PDF-Seite 11
HOS-139155 · Präparat HOS-098290
Drug/Substance Class or Drug interaction effect Recommendations concerning
Name co-administration
Grapefruit or grapefruit juice May increase tacrolimus whole Avoid grapefruit or grapefruit
blood trough concentrations and juice.
increase the risk of serious adverse
reactions (e.g., neurotoxicity, QT
prolongation) (see section 4.4).
Ciclosporin May increase tacrolimus whole The simultaneous use of
blood trough concentrations. In ciclosporin and tacrolimus
addition, synergistic/additive should be avoided (see section
nephrotoxic effects can occur. 4.4).
Products known to have May enhance nephrotoxic or Concurrent use of tacrolimus
nephrotoxic or neurotoxic neurotoxic effects of tacrolimus. with drugs known to have
effects: nephrotoxic effects should be
aminoglycosides, gyrase avoided. When co-
inhibitors, vancomycin, administration cannot be
sulfamethoxazole + avoided, monitor renal
trimethoprim, NSAIDs, function and other side effects
ganciclovir, aciclovir, and adjust tacrolimus dose if
amphotericin B, ibuprofen, needed.
cidofovir, foscarnet
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): foscarnet (HOS-110484) sulfamethoxazole (HOS-084533) ibuprofen (HOS-087884) amphotericin B (HOS-109312) trimethoprim (HOS-085184) cidofovir (HOS-110482) grapefruit juice (HOS-088787) vancomycin (HOS-110486) ganciclovir (HOS-085194)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-08T17:10:00Z · SHA-256 bf71e479a3104e9d8dd9aede574f2baf87c2d76cd8cc9266ee2ef92ed475dc55 · Passage 27fe058ee2f62d3423943030b75626c17ecf4d1bde53b7f6d6b5cf7025959525 · Zeichen 2054–3913 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.